Lampalizumab
Lampalizumab is an experimental drug that was developed by Genentech, a biotechnology company based in the United States. The drug was designed to treat geographic atrophy, a form of age-related macular degeneration (AMD) that can lead to severe vision loss and blindness.
History
Lampalizumab was first developed by Genentech, a member of the Roche Group. The drug was designed to target and inhibit the activity of complement factor D, a protein that plays a key role in the development of geographic atrophy.
In 2013, Genentech announced the results of a Phase II clinical trial, which suggested that lampalizumab could slow the progression of geographic atrophy. However, two Phase III clinical trials (known as the Spectri and Chroma trials) failed to confirm these results.
Mechanism of Action
Lampalizumab is a monoclonal antibody that targets complement factor D. By inhibiting this protein, the drug is thought to reduce the inflammatory response that contributes to the development of geographic atrophy.
Clinical Trials
The Phase II clinical trial of lampalizumab, known as the Mahalo trial, suggested that the drug could slow the progression of geographic atrophy. However, the Phase III Spectri and Chroma trials failed to confirm these results.
In the Spectri trial, patients treated with lampalizumab did not experience a significant reduction in the progression of geographic atrophy compared to those treated with a placebo. Similarly, in the Chroma trial, there was no significant difference in the progression of geographic atrophy between patients treated with lampalizumab and those treated with a placebo.
Future Development
Following the results of the Spectri and Chroma trials, Genentech announced that it would not seek regulatory approval for lampalizumab as a treatment for geographic atrophy. However, the company stated that it would continue to investigate other potential treatments for this condition.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
